Literature DB >> 18418484

Discharge Delay in Patients with Community-acquired Pneumonia Managed on a Critical Pathway.

Jeremy J Moeller1, Martin Ma, Paul Hernandez, Thomas Marrie, Claire Touchie, Ward Patrick.   

Abstract

INTRODUCTION: It has previously been reported that a critical pathway for community-acquired pneumonia (CAP) significantly reduces bed days per patient managed but results in no difference in average length of stay, suggesting that discharge criteria were not successfully implemented. The present study sought to identify factors in the timing of discharge not taken into account by discharge criteria.
METHODS: Patients admitted with CAP and placed on a pneumonia critical pathway were studied. Patients' functional and cognitive status were evaluated using the Barthel Index, Hierarchical Assessment of Balance and Mobility (HABAM) and the Mini-Mental Status Examination. Once discharge criteria were met, the patient, a family member and the treating physician were interviewed to identify other factors contributing to length of stay.
RESULTS: Thirty-one patients were enrolled in the study; 12 were discharged when they met discharge criteria and 19 stayed in hospital longer. There were no differences between patients discharged at stability versus those with an increased length of stay in terms of demographics, pneumonia severity score, functional or cognitive status at discharge using the Barthel Index (87.3+/-11.1 versus 83.8+/-8.6, respectively; P=0.46) and MMSE (27.1+/-1.1 versus 27.3+/-1.1, respectively; P=0.64); however, there was a significant difference in HABAM score at the time clinical stability was reached (22.6+/-1.3 versus 17.4+/-3.5, respectively; P=0.03), which correlated with physician and family assessments of patients' readiness for discharge.
CONCLUSIONS: HABAM may be a useful tool to identify patients at risk of remaining in hospital after objective discharge criteria are met. Additional resources may be targeted at these patients to reduce length of stay in CAP.

Entities:  

Keywords:  Community-acquired pneumonia; Critical pathway; Discharge criteria; Length of stay

Year:  2006        PMID: 18418484      PMCID: PMC2095063          DOI: 10.1155/2006/375645

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  18 in total

1.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.

Authors:  D C Rhew; G S Tu; J Ofman; J M Henning; M S Richards; S R Weingarten
Journal:  Arch Intern Med       Date:  2001-03-12

3.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

4.  Variation in management of community-acquired pneumonia requiring admission to Alberta, Canada hospitals.

Authors:  Y Jin; T J Marrie; K C Carriere; G Predy; C Houston; K Ness; D H Johnson
Journal:  Epidemiol Infect       Date:  2003-02       Impact factor: 2.451

5.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

6.  Triaging care for patients with pneumonia. Real progress.

Authors:  F M LaForce
Journal:  Arch Intern Med       Date:  1997-01-13

7.  A Hierarchical Assessment of Balance and Mobility.

Authors:  C MacKnight; K Rockwood
Journal:  Age Ageing       Date:  1995-03       Impact factor: 10.668

8.  Comparison of processes and outcomes of pneumonia care between hospitalists and community-based primary care physicians.

Authors:  William D Rifkin; David Conner; Alan Silver; Ann Eichorn
Journal:  Mayo Clin Proc       Date:  2002-10       Impact factor: 7.616

9.  Applying a prediction rule to identify low-risk patients with community-acquired pneumonia.

Authors:  T K Marras; C Gutierrez; C K Chan
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

10.  A population-based study of the costs of care for community-acquired pneumonia.

Authors:  M Bartolomé; J Almirall; J Morera; G Pera; V Ortún; J Bassa; I Bolíbar; X Balanzó; A Verdaguer
Journal:  Eur Respir J       Date:  2004-04       Impact factor: 16.671

View more
  6 in total

1.  Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.

Authors:  Thomas P Lodise; Antonio R Anzueto; David J Weber; Andrew F Shorr; Min Yang; Alexander Smith; Qi Zhao; Xingyue Huang; Thomas M File
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

2.  Risk factors, costs and complications of delayed hospital discharge from internal medicine wards at a Canadian academic medical centre: retrospective cohort study.

Authors:  Anthony D Bai; Cathy Dai; Siddhartha Srivastava; Christopher A Smith; Sudeep S Gill
Journal:  BMC Health Serv Res       Date:  2019-12-04       Impact factor: 2.655

3.  Initiatives for improving delayed discharge from a hospital setting: a scoping review.

Authors:  Lauren Cadel; Sara J T Guilcher; Kristina Marie Kokorelias; Jason Sutherland; Jon Glasby; Tara Kiran; Kerry Kuluski
Journal:  BMJ Open       Date:  2021-02-11       Impact factor: 2.692

4.  Effect of zinc versus vitamin A supplementation on pediatric patients with community-acquired pneumonia.

Authors:  Aya Saied; Radwa Maher El Borolossy; Mourad Alfy Ramzy; Nagwa A Sabri
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

5.  Impact and experiences of delayed discharge: A mixed-studies systematic review.

Authors:  Antonio Rojas-García; Simon Turner; Elena Pizzo; Emma Hudson; James Thomas; Rosalind Raine
Journal:  Health Expect       Date:  2017-09-12       Impact factor: 3.377

6.  Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Authors:  Thomas Lodise; Sam Colman; Daniel S Stein; David Fitts; Lisa Goldberg; Elizabeth Alexander; Patrick J Scoble; Jennifer Schranz
Journal:  Open Forum Infect Dis       Date:  2020-04-24       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.